Next 10 |
2024-05-09 17:49:08 ET More on Xencor Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript Xencor slips as Piper cuts citing patient death in cancer study Seeking Alpha’s Quant Rating on Xencor Historical earnings data for Xencor Financial info...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlig...
2024-04-25 18:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-16 07:00:03 ET Kaveri Pohlman from BTIG issued a price target of $38.00 for XNCR on 2024-04-16 05:16:00. The adjusted price target was set to $38.00. At the time of the announcement, XNCR was trading at $20.11. The overall price target consensus is at $56.00 with...
2024-04-09 08:17:05 ET More on Xencor Xencor, Inc. (XNCR) Q4 2023 Earnings Call Transcript Xencor: Standing Out With XmAb Technology Xencor slips as Piper cuts citing patient death in cancer study Read the full article on Seeking Alpha For further det...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 2...
2024-03-16 19:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-- Clinical development focus on high-potential XmAb ® T cell engagers and selective dual checkpoint inhibitor, vudalimab -- -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced bey...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-24 17:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlig...
2024-04-25 18:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-16 07:00:03 ET Kaveri Pohlman from BTIG issued a price target of $38.00 for XNCR on 2024-04-16 05:16:00. The adjusted price target was set to $38.00. At the time of the announcement, XNCR was trading at $20.11. The overall price target consensus is at $56.00 with...